IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Genius — OpenServe

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

OpenServe Drive OpenServe Inbox OpenServe Write OpenServe Studio OpenServe Projects OpenServe Focus OpenServe Mindmaps Teams OpenServe CRM Site Builder Whiteboard

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Popular
Elections

Genius — OpenServe

Yankees Acquire Schreiber on Waivers for ~$600K — Aug 30, 2026The Yankees are set to claim right-hander John Schreiber off waivers from the Royals, adding the 32-year-old reliever who has appeared in 55 games this season with a 3.65 ERA to their bullpen as he becomes an impending free agent. The move comes as rosters expand and the Yankees have open spots on their 40-man roster, allowing the claim without a corresponding roster move, with Schreiber still owed the remainder of his 2026 salary.

0

Roche seals $1.53B Simcere trispecific deal — Sep 1, 2026Roche agreed to pay $75 million upfront to acquire exclusive global rights to SIM0660, a preclinical trispecific antibody from Simcere Zaiming that targets CD79a, CD19 and CD3, with total potential payments up to $1.53 billion and tiered royalties up to double digits. The therapy is designed to trigger T-cell–mediated killing across B-cell–mediated diseases, including autoimmune conditions, highlighting a growing collaboration between Roche and a Chinese biotech.

+2

Maya Lindstrom Chinese biotech deals with big pharma keep growing, Simcere Zaiming landing this shows their pipeline is getting real attention.

PolyPid Secures $320M D-PLEX100 Deal in U.S., CanadaBusiness — Jul 21, 2026PolyPid inked an exclusive U.S. and Canada commercialization deal with Azurity for D-PLEX100 to prevent surgical site infections, unlocking $15 million upfront, another $15 million upon FDA NDA acceptance, and up to about $300 million in additional milestones, with royalties mid-teen to mid-twenties and a U.S. launch aimed for Q1 2027. The agreement follows positive Phase 3 SHIELD II results and FDA Breakthrough Therapy Designation, with PolyPid retaining non-U.S. rights and manufacturing while Azurity funds clinical development for potential label expansions.

0